Startseite>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>DDD107498 succinate

DDD107498 succinate (Synonyms: DDD107498 succinate; DDD-498 succinate; M5717 succinate)

Katalog-Nr.GC35820

DDD107498-Succinat (DDD-498-Succinat) ist ein potenter und oral aktiver Malariawirkstoff, der mehrere Lebenszyklusstadien des Parasiten hemmt, mit einem EC50-Wert von 1 nM gegen P.

Products are for research use only. Not for human use. We do not sell to patients.

DDD107498 succinate Chemische Struktur

Cas No.: 2444781-71-7

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
242,00 $
Auf Lager
5mg
189,00 $
Auf Lager
10mg
297,00 $
Auf Lager
50mg
950,00 $
Auf Lager
100mg
1.431,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

DDD107498 succinate (DDD-498 succinate) is a potent and orally active antimalarial agent, inhibits multiple life-cycle stages of the parasite, with an EC50 of 1 nM against P. falciparum 3D7. DDD107498 succinate inhibits protein synthesis by targeting eEF2/CaMKIII, with an EC50 of 2 nM for WT-PfeEF2[1]. EC50: 1 nM (3D7 parasites), 2 nM (WT-PfeEF2)[1]

DDD107498 exhibits an ED90 of 0.57 mg/kg after a single oral dose in mice infected with the rodent parasite P. berghei[1].

[1]. BaragaÑa B, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015 Jun 18;522(7556):315-20.

Bewertungen

Review for DDD107498 succinate

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DDD107498 succinate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.